Covered recipient · General Payments record
OMAR SHAHATEET
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$3,066.07
- Reported across 64 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $680.57 | 15 |
| Education | $7.09 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $250.73 | 5 |
| Ardelyx, Inc. | $155.17 | 3 |
| Acerta Pharma LLC | $140.59 | 3 |
| BAXTER HEALTHCARE | $75.08 | 1 |
| ANI Pharmaceuticals, Inc. | $50.58 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.51 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.23 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116108363 | CMS |
| Amgen Inc. | $4.31 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116108370 | CMS |
| Amgen Inc. | $10.36 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116108376 | CMS |
| Amgen Inc. | $99.81 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116108356 | CMS |
| Amgen Inc. | $121.02 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117680958 | CMS |
| ANI Pharmaceuticals, Inc. | $20.70 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091163484 | CMS |
| ANI Pharmaceuticals, Inc. | $13.49 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091151312 | CMS |
| ANI Pharmaceuticals, Inc. | $16.39 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091169020 | CMS |
| Ardelyx, Inc. | $17.14 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146707136 | CMS |
| Ardelyx, Inc. | $122.19 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146707138 | CMS |
| Ardelyx, Inc. | $15.84 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146707140 | CMS |
| AstraZeneca Pharmaceuticals LP | $7.09 | 01/11/2024 | Education | Undisputed | 01/23/2026 | 1105639476 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.95 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104526988 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.55 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104307074 | CMS |
| Baxter Healthcare | $75.08 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120648891 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.51 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118237100 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.